Search Tag: prostate cancer
2025 17 Nov
Magnetic resonance imaging guides prostate cancer diagnosis, yet availability, variability, workflow and cost can limit its use. Multiparametric ultrasound (mpUS) supported by artificial intelligence offers a different route that may be easier to implement at scale. A three-dimensional mpUS model was evaluated for its ability to localise clinically...Read more
2025 17 Nov
Advanced prostate cancer (APC), encompassing stages such as metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (mCRPC), presents complex challenges for diagnosis and treatment. Traditional imaging methods, including CT and bone scans, have been widely used to assess metastatic disease, but their limitations...Read more
2025 24 Sep
Prostate cancer remains a major global burden, while diagnostic pathways continue to evolve to balance accuracy, invasiveness and resource use. Multiparametric MRI is central to noninvasive assessment but can be affected by motion, interpretation variability and scan duration. Researchers have reported an in silico evaluation of MRI histopathology,...Read more
2025 08 Sep
Detecting the return of prostate cancer after initial treatment remains a major challenge, particularly for patients with low prostate-specific antigen (PSA) levels. Conventional imaging methods often fail to identify disease recurrence at this early stage, limiting treatment options. Prostate-specific membrane antigen (PSMA) targeted PET imaging has...Read more
2025 02 Sep
Magnetic resonance imaging has become central to prostate cancer diagnosis and risk stratification, yet variability in image quality can undermine clinical pathways. A multi-institutional analysis assessed how prostate imaging quality, graded with the updated Prostate Imaging Quality Score version 2 (PI-QUAL v2), affects the diagnostic performance...Read more
2025 25 Aug
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide and poses a major burden on health systems. While biparametric MRI is recommended as a primary diagnostic approach, its standard assessment method—PI-RADS—has limitations, particularly a high false-positive rate. These limitations often result in unnecessary biopsies,...Read more
2025 31 Jul
Prostate cancer remains the most diagnosed cancer and a leading cause of cancer-related deaths among European men. In response, the Council of the European Union has revised its screening recommendations to include prostate cancer, encouraging member states to explore early detection programmes. Yet, unlike other established screening initiatives,...Read more
2025 31 Jul
Prostate cancer remains the most diagnosed cancer and a leading cause of cancer-related deaths among European men. In response, the Council of the European Union has revised its screening recommendations to include prostate cancer, encouraging member states to explore early detection programmes. Yet, unlike other established screening initiatives,...Read more
2025 01 Jul
Prostate cancer remains a major global health issue for men, and timely diagnosis is vital to ensuring effective treatment. Accurate segmentation of prostate cancer (PCa) lesions on MRI scans is a critical step in evaluating tumour extent, guiding biopsies and supporting treatment decisions. While magnetic resonance imaging (MRI) has proven effective...Read more
2025 15 Jun
Prostate-specific membrane antigen (PSMA) PET imaging has become a key tool in the detection and staging of prostate cancer, offering improved diagnostic capabilities over traditional imaging methods. However, variability in how these scans are interpreted has posed challenges for consistent clinical decision-making. The introduction of the PSMA...Read more
2025 04 May
Accurate localisation of prostate lesions is essential for the effective diagnosis and management of prostate cancer, which remains one of the most common cancers in men across Europe and North America. Multiparametric MRI (mpMRI) plays a crucial role in the detection of clinically significant prostate cancer, offering benefits such as reducing overdiagnosis...Read more
2025 14 Apr
Accurately classifying prostate cancer (PCa) aggressiveness is essential for effective treatment planning, yet traditional methods such as biopsy carry risks and may lead to sampling errors. Biparametric MRI (bpMRI), a noninvasive imaging technique, has gained prominence in PCa staging. The rise of deep learning (DL) offers potential for automating...Read more
2025 17 Feb
Prostate cancer remains one of the most prevalent malignancies in men, with early and accurate detection playing a crucial role in determining patient outcomes. Conventional imaging techniques such as MRI, CT and bone scans often struggle to identify small or early-stage metastatic lesions, particularly in cases of biochemical recurrence (BCR)....Read more
2025 08 Feb
Prostate cancer is one of the most common malignancies among men, and early detection is crucial for optimising treatment outcomes. However, a major challenge in prostate cancer diagnosis lies in distinguishing clinically significant prostate cancer (csPCa) from indolent cases that may not require immediate intervention. Traditional diagnostic...Read more
2024 25 Nov
Prostate cancer continues to be a leading cause of cancer-related morbidity among men worldwide, necessitating effective and reliable diagnostic tools. Magnetic resonance imaging (MRI) of the prostate, interpreted using the Prostate Imaging-Reporting and Data System (PI-RADS), has emerged as a significant advancement in the early detection of...Read more
2024 06 Oct
Prostate cancer (PCa) remains a significant health concern, and the accurate diagnosis and characterisation of its severity are crucial for effective treatment. Currently, biopsy and multiparametric MRI (mpMRI) are standard diagnostic tools, though they are limited in sensitivity and specificity. A novel approach using Sodium-23 (23Na) MRI has...Read more
2024 01 Oct
Metastatic castration-resistant prostate cancer (mCRPC) represents a highly challenging stage of prostate cancer, often characterised by heterogeneous tumour behaviour across different metastases. This complexity, referred to as intrapatient intermetastatic heterogeneity (IIH), can significantly affect treatment outcomes. Recent advances in molecular...Read more
2024 23 Sep
Prostate cancer (PCa) remains one of the most common malignancies among men worldwide, and accurate staging is crucial for effective treatment planning. Recently, positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA) tracers has improved the detection of PCa metastases. One of the newer tracers,...Read more
2024 16 Sep
Prostate cancer is the second most common cancer among men worldwide, making early detection crucial for reducing morbidity and mortality rates. One of the key tools for identifying clinically significant prostate cancer (csPCa) is multiparametric magnetic resonance imaging (mpMRI). However, the process of detecting prostate cancer through mpMRI...Read more
2024 16 Sep
Active surveillance (AS) has become a widely recommended approach for managing patients with low or favourable intermediate-risk prostate cancer. This strategy aims to delay or avoid radical treatments and their associated side effects while maintaining effective cancer control. Magnetic resonance imaging (MRI), particularly multiparametric MRI...Read more
2024 22 Jul
Over the past decade, MRI-targeted biopsy has emerged as a superior method for detecting clinically significant prostate cancer (csPCa) compared to systematic biopsy. Randomized studies have consistently demonstrated its efficacy. However, MRI fails to detect up to one-third of csPCa cases. This shortfall is influenced by histopathologic features...Read more
2024 19 Jun
Prostate cancer (PCa) is highly prevalent globally among men, necessitating improved diagnostic accuracy, especially for clinically significant cases (csPCa) requiring aggressive treatment to reduce mortality. While prostate-specific antigen (PSA) is commonly used for screening, its reliance leads to over-diagnosis concerns due to lack of cancer...Read more
2024 19 Jun
Prostate cancer (PCa) treatment strategies are evolving, with increasing interest in focal therapy (FT) as a less invasive alternative to traditional prostatectomy and radiation therapy. FT aims to eradicate cancer while preserving quality of life, making accurate cancer contouring crucial for treatment success. However, conventional methods often...Read more
2024 29 May
While multiparametric magnetic resonance imaging (mpMRI) has become integral in prostate cancer (PCa) diagnosis, there's a debate regarding the inclusion of dynamic contrast-enhanced (DCE) sequences in future PI-RADS iterations due to questionable benefits. To address time constraints, biparametric (bp) protocols, omitting DCE sequences, have...Read more
2024 02 May
Active surveillance (AS) is endorsed by the European Association of Urology (EAU) for low to favourable intermediate-risk prostate cancer (PCa) patients. It aims to delay or avoid radical treatments while maintaining oncological outcomes. AS's safety is supported by trials like ProtecT and PIVOT, despite potential understaging and undergrading....Read more
2024 05 Apr
A groundbreaking study presented at the Society of Interventional Radiology Annual Scientific Meeting unveils the potential of a minimally invasive treatment for prostate cancer using MRI-guided transurethral ultrasound ablation (TULSA). This innovative approach offers an effective alternative to traditional treatments like surgery or radiation,...Read more
2024 05 Apr
A groundbreaking study presented at the Society of Interventional Radiology Annual Scientific Meeting unveils the potential of a minimally invasive treatment for prostate cancer using MRI-guided transurethral ultrasound ablation (TULSA). This innovative approach offers an effective alternative to traditional treatments like surgery or radiation,...Read more
2024 09 Dec
<marquee behavior="slide" direction="left" scrollamount="30"> <h2 style="text-align: center;"><font color="#000099"><b>Find ESMO On Social Media</b> </font></h2><div style="text-align: center;"><a href=https://www.twitter.com/myesmo target="_blank"><img src="/uploads/twnew.png" style="text-align: initial;" width=65 height=65></a><Read more
2024 18 Dec
<marquee behavior="slide" direction="left" scrollamount="30"> <h2 style="text-align: center;"><font color="#000099"><b>Find ESMO On Social Media</b> </font></h2><div style="text-align: center;"><a href=https://www.twitter.com/myesmo target="_blank"><img src="/uploads/twnew.png" style="text-align: initial;" width=65 height=65></a><Read more
2023 22 Aug
According to a new study, a 10-minute MRI scan could be used to screen men for prostate cancer. The scans demonstrated significantly higher accuracy in diagnosing cancer compared to blood tests that rely on finding high levels of a protein known as PSA. MRI technology successfully identified several serious cancers that would have gone undetected...Read more